Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
Status:
Withdrawn
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The investigators are testing subtenon carboplatin in combination with vincristine and
topotecan given by vein in the hopes of finding a drug combination that may be effective
against retinoblastoma that has come back (recurrent) or is resistant to other treatment
(refractory).
The goals of this study are:
- To decide if the drug combination is a useful treatment for recurrent or refractory
retinoblastoma
- To test the safety of the drug combination and to see what kind of effects (good and
bad) can be expected from the drug combination
- To measure visual changes before and after the study therapy
- To use a special MRI scan to measure brain function involved in vision processing, both
before and after the study therapy
In this study, the investigators are also testing a new experimental way of giving
carboplatin "subtenon carboplatin". The carboplatin will be given directly in the eye through
a needle placed under the covering of the eye. This is to try to get more carboplatin to the
retinoblastoma inside the eye.